CRISPR Therapeutics AG
CRSP Healthcare Biotechnology
CRISPR Therapeutics AG’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 90.6% from fiscal 2024. In the quarter to June 2026, revenue grew 1,041.4%, EPS grew 60.8% and free cash flow grew 26.2%, each against the same quarter a year earlier.
Follow CRSP
CRISPR Therapeutics AG (CRSP) Beneish M-score
CRISPR Therapeutics AG's Beneish M-score for fiscal 2025 cannot be worked out: days’ sales in receivables index cannot be worked out.
Beneish M-score, annual
Embed this chart
Annual newest first
| Period | Beneish M-score | Change (points) |
|---|---|---|
| FY2024 | −4.94 | (277.43) |
| FY2023 | 272.49 | (24,929.34) |
| FY2022 | 25201.83 | 24,070.61 |
| FY2021 | 1131.22 | 692.99 |
| FY2020 | 438.23 | 357.82 |
| FY2019 | 80.41 | 87.97 |
| FY2018 | −7.56 | (10.76) |
| FY2017 | 3.19 | (12.70) |
| FY2016 | 15.89 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Days’ sales in receivables index | — | — | n/a | — |
| Gross margin index | 1.00 | — | 0.53 | |
| Asset quality index | 0.95 | — | 0.38 | |
| Sales growth index | 0.09 | — | 0.08 | |
| Depreciation index | 0.87 | — | 0.10 | |
| SG&A index | 10.71 | — | −1.84 | |
| Total accruals to total assets | (0.10) | — | −0.49 | |
| Leverage index | 1.68 | — | −0.55 | |
| Beneish M-score | n/a — days’ sales in receivables index cannot be worked out | — | ||
How the Beneish M-score works
M = −4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI (Beneish, 1999): eight changes in the accounts from one fiscal year to the next, which the model weighs for the pattern seen in companies that later restated their earnings. Higher is worse.
| below −2.22 | Low — no pattern the model associates with manipulation |
|---|---|
| −2.22 to −1.78 | Elevated |
| above −1.78 | Flagged by the model |
−1.78 is the cut-off usually quoted from the paper, −2.22 a common conservative one. A statistical screen, not a finding of wrongdoing.
When asset quality, depreciation or SG&A cannot be worked out, that index is set to 1, as Beneish did, and the breakdown says so; with all three missing there is no score. Depreciation includes amortisation, and asset quality leaves out securities. Not worked out for banks, insurers and REITs.
Beneish M-score against peers
| Company | Beneish M-score |
|---|---|
| MIRM Mirum Pharmaceuticals, Inc. compare | −2.5× |
| TVTX Travere Therapeutics, Inc. compare | −1.7× |
| PTCT PTC Therapeutics, Inc. compare | −1.5× |
| COGT Cogent Biosciences, Inc. compare | — |
| ORKA Oruka Therapeutics, Inc. compare | — |
| ERAS Erasca, Inc. compare | — |
| SRRK Scholar Rock Holding Corporation compare | — |
| DFTX Definium Therapeutics, Inc. compare | — |
| CRSP CRISPR Therapeutics AG | — |
What Beneish M-score is
The Beneish M-Score combines eight year-on-year changes in the accounts into a statistical screen for patterns seen in companies that overstated earnings.
−4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI